openPR Logo
Press release

Antisense Oligonucleotides Market ,Quantitative Analysis, Current and Future Trends, 2014 - 2020

03-06-2018 12:34 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Future Market Insights

Antisense Oligonucleotides Market ,Quantitative Analysis,

Antisense oligonucleotides (ASOs) are 15–25 nt oligonucleotides designed to tie complementary RNA targets for the degradation. They are synthesized so that they can be used to block disease processes by altering the synthesis of a specific protein. ASOs offers promising treatment options for a range of medical disorders. They facilitate the development of therapeutics affecting protein targets which cannot be treated with protein therapeutics. They can target a particular malfunctioning gene, interfere with RNA function at cellular level, and can also be silenced or modulated. It allows modifications in immune system that facilitates treatment of a wide range of autoimmune disorders – that cannot be treated with available drugs. It is easy to scale up the commercial scale GMP production of these oligonucleotides compared to other biologic therapies. Moreover, the side effects of antisense oligonucleotides are minimal and can be controlled with ease as compared to other class of drugs.

Though, the antisense oligonucleotides market has witnessed four FDA approvals [fomivirsen (Vitravene) approved in 1998 – which was discontinued due to low demand; pegaptanib (Macugen) in 2004; mipomersen (Kynamro) in 2013; and eteplirsen (Exondys 51) in 2016). However, this market is yet to achieve recognition as a valuable drug category like biologics, small molecules, and gene and cell therapy. However, in December 2016, this was projected to change with the approval of nusinersen (Spinraza) for treating spinal muscular atrophy (SMA), which is one of the most common genetic cause for infant mortality with no approved treatments. Spinraza has shown unprecedented results for the treatment of SMA in clinical trials.

Request For Report sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5377

Antisense Oligonucleotides Market: Drivers and Restraints Strong pipeline of antisense oligonucleotides and increased focused on large number of product approvals and commercialization are some of the primary factors driving the growth of the global antisense oligonucleotides market. Moreover, significant advances in the field of antisense oligonucleotides at a therapeutic or clinical level is further contributing to the growth of the global antisense oligonucleotides market. However, the global antisense oligonucleotides market is grappling with numerous challenges related to diversity of oligonucleotides, delivery, and regulatory complexity. Despite several advancements at clinical levels, the delivering of active oligonucleotide to the actual site within target cells is still one of the major challenges hindering the growth of the global antisense oligonucleotides market. In addition to this, developing a new set of unique regulatory guidelines is another challenge limiting the growth of the global antisense oligonucleotides market.

Antisense Oligonucleotides Market: Overview Although the development of oligonucleotide therapeutics commenced in 1970s, FDA has approved only four oligonucleotide drugs (of which fomivirsen was discontinued) nearly a half century later. However, the filed is gaining momentum and is set to offer promising growth opportunities with a strong pipeline of 135 oligonucleotides in various stages of clinical trials. Even when the market performance of antisense oligonucleotides is not predictable as like other segments of the industry, the future looks very promising primarily reflected by the leadings players in the market and the amount of research and development investments.

Antisense Oligonucleotides Market: Regional Outlook

Geographically, the global antisense oligonucleotides market is segmented into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America clearly dominates the global antisense oligonucleotides market due to a strong product pipeline and increasing number of FDA approvals in the region.

Request For Table Of Content @ https://www.futuremarketinsights.com/toc/rep-gb-5377

Antisense Oligonucleotides Market: Key Players

Some of the players identified in the global antisense oligonucleotides market include Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Biogen, Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals, Inc., Atlantic Pharmaceuticals, Inc., Enzon Pharmaceuticals, Inc., Bio-Path Holdings, Inc., Gene Signal International SA, GlaxoSmithKline plc, Geron Corporation, Gradalis, ICO Therapeutics, Aptose Biosciences, Marina Biotech, miRagen Therapeutics, Inc., Synlogic, Inc., OncoGenex Pharmaceuticals Inc., Pharmaxis Ltd, Regulus Therapeutics Inc., Rexahn Pharmaceuticals, Inc., and RXi Pharmaceuticals, among others.

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes,technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends. technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

Future Market Insights
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antisense Oligonucleotides Market ,Quantitative Analysis, Current and Future Trends, 2014 - 2020 here

News-ID: 966457 • Views:

More Releases from Future Market Insights

Electronic Tongue Market will grow USD 774.2 million by 2035, at a 4.5% CAGR, fueled by demand for smart diagnostics and medical R&D.
Electronic Tongue Market will grow USD 774.2 million by 2035, at a 4.5% CAGR, fu …
The global electronic tongue market is advancing rapidly, poised to reach USD 497.9 million in 2025 and climb to USD 774.2 million by 2035, growing at a promising 4.5% CAGR. The increasing demand for precision diagnostics, pharmaceutical quality control, and personalized medicine is driving this technological surge, positioning the electronic tongue as a futuristic, non-invasive diagnostic instrument in healthcare and pharmaceuticals. Electronic tongues, by design, mimic human sensory functions through an
ESD Tapes and Labels market will expand USD 4,253.3 million by 2035, growing at 4.5% CAGR with strong electronics and aerospace demand.
ESD Tapes and Labels market will expand USD 4,253.3 million by 2035, growing at …
The global market for ESD (electrostatic discharge) tapes and labels is entering a new decade of expansion driven by technological innovation, the rise of miniaturized electronics, and heightened quality standards in manufacturing. Valued at USD 2,738.8 million in 2025, the market is expected to reach USD 4,253.3 million by 2035, expanding at a steady 4.5% CAGR. This reflects a world increasingly dependent on efficient anti-static solutions that ensure the protection
Catalase Market will rise USD 575.9 million by 2035 at 3.1% CAGR, driven by sustainable innovations and expanding applications.
Catalase Market will rise USD 575.9 million by 2035 at 3.1% CAGR, driven by sust …
The global market for catalase is preparing for steady long-term expansion, driven by green chemistry, renewable sourcing, and biotechnology-driven production upgrades. Projected to reach USD 424.5 million in 2025 and USD 575.9 million by 2035, the industry's 3.1% CAGR reflects its broadening influence across critical sectors including food and beverages, pharmaceuticals, textiles, and personal care. With growing concerns about sustainability, efficiency, and safety, catalase is emerging as a vital biocatalyst
Quillaia Extract market is set to reach USD 1,826.9M by 2035 at 5.8% CAGR fueled by natural, functional, and sustainable trends.
Quillaia Extract market is set to reach USD 1,826.9M by 2035 at 5.8% CAGR fueled …
The global Quillaia extract market is entering a period of unprecedented growth, reflecting the world's shift toward natural, functional, and nutrient-rich ingredients. Projected to increase from USD 1,039.6 million in 2025 to USD 1,826.9 million by 2035 at a robust 5.8% CAGR, the industry's future is shaped by consumer demand for healthier, eco-friendly products and manufacturers' determination to stay ahead through innovation, expansion, and diversification. Over the past few years, Quillaia

All 5 Releases


More Releases for Antisense

Antisense Oligonucleotide Therapeutics Market
Antisense Oligonucleotide Therapeutics Market worth $ 64.64 Billion by 2030 - Exclusive Report by Insight Analytics Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global Antisense Oligonucleotide Therapeutics Market- by Therapy (Monotherapy and Combination), Molecule Target Indication (DNA Molecule and RNA Molecule), Target Indication (Duchenne Muscular Atrophy, Spinal Muscular Atrophy, Familial Chylomicronemia Syndrome, Amyotrophic Lateral Sclerosis, Familial Partial Lipodystrophy, Hereditary Transthyretin-Mediated (hatter) Amyloidosis, Huntington's Disease
Antisense RNAi Therapeutics Market: Size, Share, and Trends Analysis
The antisense RNA interference (RNAi) therapeutics market represents a burgeoning sector within the pharmaceutical industry, offering innovative treatments for a wide range of diseases by modulating gene expression at the post-transcriptional level. Antisense RNAi therapeutics leverage the RNA interference mechanism to target specific messenger RNA (mRNA) molecules, thereby inhibiting the production of disease-associated proteins. As of [current year], the market for antisense RNAi therapeutics is experiencing rapid growth, driven by advancements
Antisense Oligonucleotide Therapeutics Market 2024-2031 | Exclusive Study Report
Antisense Oligonucleotide Therapeutics Market worth $ 64.64 Billion by 2030 - Exclusive Report by Insight Analytics Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global Antisense Oligonucleotide Therapeutics Market- by Therapy (Monotherapy and Combination), Molecule Target Indication (DNA Molecule and RNA Molecule), Target Indication (Duchenne Muscular Atrophy, Spinal Muscular Atrophy, Familial Chylomicronemia Syndrome, Amyotrophic Lateral Sclerosis, Familial Partial Lipodystrophy, Hereditary Transthyretin-Mediated (hatter) Amyloidosis, Huntington's Disease
Current Trends: Antisense & RNAi Therapeutics Market in-depth Analysis
The global antisense & rnai therapeutics market is estimated to surpass $2,252.6 million by 2027, exhibiting a CAGR of 8.4% from 2020 to 2027. The report offers a thorough analysis of global antisense & rnai therapeutics market with detailed study of various aspects of the market such as market dynamics, vital segments, major geographies, key players, and competitive landscape. The report provides a clear picture of the current market situation and future
Antisense Oligonucleotides Market Global Trends, Analysis and Forecast 2027
Antisense oligonucleotides (ASOs) are 15–25 nt oligonucleotides designed to tie complementary RNA targets for the degradation. They are synthesized so that they can be used to block disease processes by altering the synthesis of a specific protein. ASOs offers promising treatment options for a range of medical disorders. They facilitate the development of therapeutics affecting protein targets which cannot be treated with protein therapeutics. They can target a particular malfunctioning
Antisense Oligonucleotides Market Opportunity Analysis, 2026
Antisense oligonucleotides are short, single stranded RNA or DNA molecules. Antisense oligonucleotides do not modulate the activity of already formed proteins, however they act before proteins are produced at the level of messenger RNA in the cell. Antisense oligonucleotides is used in treatment of oncology, Central nervous system therapeutics, inflammation therapeutics, diabetes, asthma, hair loss, etc. Antisense oligonucleotides is also used in genomics. Some examples of antisense nucleotides are fomivirsen